PubMed Health⌕ Search

Biomedical subjects

E Pommatau

Publications and source records attributed to E Pommatau.

At least 19 recordsLinked to original sources
PubMed1986

[Survival and prognostic factors in cerebral metastases of breast cancer].

A number of prognostic factors have emerged from a retrospective study of 83 patients with breast cancer associated with a solid intracerebral tumour (59%), or meningeal invasion (33%) or both (8%). The median survival was 4 months without significant difference between breast tumours and meningeal carcinomatosis. Women in pre-menopause at the initial diagnosis of breast cancer (P less than or equal to 0.05) or who were 50 years of age when the cerebral metastasis occurred (P less than or equal to 0.05) or who had only one metastasis (P less than or equal to 0.02) had a better prognosis. During meningeal carcinomatosis, CSF protein and carcinoembryonic antigen levels have no prognostic value. All patients with intracerebral tumour had been irradiated (40 Gy over 4 weeks). The tumour was removed whenever possible. Intrathecal or systemic chemotherapy and hormone therapy seem to be favourable prognostic factors. This would suggest that chemotherapy may increase the survival of patients with this type of breast cancer, but only randomized studies will demonstrate its true effectiveness.

Brain Neoplasms↗
PubMed1985

Stage III non-seminomatous germ cell tumours of the testis--patients treated at the Centre Leon Berard.

The study of the survival of a series of patients with stage III non-seminomatous germ cell tumours of the testis enables us to confirm two points: the use of cis-platinum has multiplied the survival rate for stage III patients by 3, the concept of stage III includes various metastatic states with different prognoses. The use of a sub-classification, like that proposed by Samuels, allows for a better definition of the natural history of these lesions.

Combined Modality Therapy↗
PubMed1984

[Controlled study of the analgesic efficacy of 2 drugs: tiapride versus aspirin].

Analgesic effect of aspirin 500 mg IM or IV and tiapride 300 mg IM or IV was compared in a double blind controlled study. Twenty-four patients with active cancer were each given both drugs successively, over 48 hours. No difference was demonstrated in analgesic effects of tiapride (14/24: 58%) and aspirin (11/24: 46%), or in toxicity which was minor for both drugs.

Adult↗
PubMed1982

[Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].

A randomized trial was done in 98 post-menopausal women with breast cancer. Hormonal receptors had not been assayed in any patient. Patients were given hormonal therapy with tamoxifen and drostanolone propionate (n = 34), or chemotherapy with the CMF protocol (n = 30), or a combination of both (n = 34). The results are in favour of hormonal therapy alone, which gave the best immediate objective responses, the least adverse side-effects, and possibly improved survival rates.

Androstanols↗
PubMed1980

[Operable carcinoma of the breast. Prognostic value of estradiol receptors. Preliminary report (author's transl)].

151 women were treated for potentially curable breast cancer. Their tumors were routinely analysed for estrogen receptors by the dextran-coated charcoal technic. Data were analyzed in relation to several parameters: age, age of menstruation, menopausal status, tumor size, TNN staging, axillary node status, nature of treatment. We have examined the pronostic implication of an ER negative content (ER-) in the primary tumor. We have found that the absence of detectable estrogen receptor in primary breast tumor appears to be correlated with a short disease free interval. In positive axillary node patients the value of the disease free interval is significantly shorter in ER- than in ER+ group: 11.5 months versus 23.5 (p less than 0.01).

Adult↗
PubMed1980

Cisplatinumdiamminodichloride (CPDD) in chemotherapy of cancers: a phase II therapeutic trial.

We have conducted a phase II trial of cisplatinumdiamminodichloride (CPDD) which not only demonstrated its remarkable activity in embryonic carcinoma of the testes, but also in ovarian carcinoma, in melanoma, and in epidermoid carcinoma, especially of the head and of the uterus cervix. Its toxicity, manifested mainly in the digestive and renal tracts, confines its administration to hospitalized patients only. This compound is now indicated in combination therapy for the above-mentioned tumors.

Adolescent↗
PubMed1979

[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial].

We have conducted a phase II trial of cisdiammino-dichloro platinum (CDDP) which demonstrates its remarkable activity in testis embryonic carcinoma, in ovary carcinoma and in epidermoid cancers, especially head and neck and uterus cervix carcinoma. Its toxicity in mainly digestive and renal. This compound is now indicated in combinations in the case of the above mentioned tumors.

Adolescent↗
PubMed1978

Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast.

The effects of tamoxifen on cortisol binding globulin (CBG) and sex hormone binding globulin (SHBG) were studied in 25 women and one man with breast cancer. These patients were in various endocrine states according to age (15 post-menopausal women) or previous endocrine surgery (ovariectomy, two patients; ovariectomy plus adrenal surgery, five patients; hypophysectomy, three patients; ovariectomy plus hypophysectomy, two patients). The administration of tamoxifen (20-40 mg/day) resulted in increases in the level of CBG in all patients (mean rise in binding capacity 10.8 microgram cortisol/100 ml plasma) and in the level of SHBG in 21 patients (mean rise in binding capacity 0.79 microgram dihydrotestosterone/100 ml plasma for all patients). These increases were positively correlated. They were not associated with any alteration in the association constants of the steroid binding globulins. The effect of tamoxifen on CBG diminished with increasing age. The changes in the levels of CBG and SHBG were independent of the endocrinological state of the patient. It is inferred that tamoxifen has a direct oestrogen-like action on the liver which results in increased production of CBG and SHBG. Tamoxifen therapy for carcinoma of the breast appeared to be least effective in those patients in whom the drug caused the highest increase in the concentration of CBG.

Adult↗
PubMed1978

[Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].

Adding duborimycin to the association of vincristine + DTIC in the treatment of malignant melanoma produces therapeutic results interesting but not statistically significant and not counter-balancing the toxic side effects. This study confirms the lack of positive results of polychemotherapy in melanoma as compared to treatment by an efficacious single drug therapy (DTIC); it also emphasizes the necessity of randomized studies so that valuable comparisons may be done.

Antibiotics, Antineoplastic↗
PubMed1977

[Polychemotherapy of advanced breast cancer. Triple combination with doxorubicin. Analysis of 209 observation].

Two hundred and nine patients with breast cancer in an advanced stage were treated according to a chemotherapeutic regimen associating doxorubicin, vincristine and methotrexate, administered in courses of 5 days every three weeks. This analysis deals only with the short range results; they confirm those of a previous randomized study. A global objective response was obtained in 187 cases (89%) and a measurable regression of the lesions in 150 cases (71%); in these later cases 90 (43%) had a regression of more than 50 per cent. The most striking effects, often rapidly observed, involve sites which are not generally sensitive: liver (40%), pleura (24%) and bone (only 6%, but 8 times out of 10 a definite action on the pain syndrome). Side effects were, on the whole, acceptable (only one severe hematologic complication); however, the risk of myocardiac toxocity due to the accumulation of doxorubicin limits the utilization of this association. It thus needs to be relayed by other drug regimens which are included in a program of long term action, but has interesting characteristics as induction chemotherapy.

Adult↗
PubMed1976

The valve of chemotherapy in the treatment of testicular dysembryoplastic tumors.

Chemotherapy appears to be of help in treating dysembryoplastic testicular tumors. It seems better to treat first by surgery (lymphadenectomy) if possible, then (a) if no nodes are involved or only one has been discovered by microscope examination, with chemotherapy for one year; or (b) if two or more nodes are involved, with irradiation of the nodes and chemotherapy. Even if lymphadenectomy is not possible, one course of chemotherapy followed by cobalt and more chemotherapy can bring results in some cases.

Cyclophosphamide↗